TY - JOUR
T1 - Effects of sodium thiosulfate on vascular calcification in end-stage renal disease
T2 - A pilot study of feasibility, safety and efficacy
AU - Mathews, Santhosh Jay
AU - De Las Fuentes, Lisa
AU - Podaralla, Prashanth
AU - Cabellon, Anton
AU - Zheng, Sijie
AU - Bierhals, Andrew
AU - Spence, Karen
AU - Slatopolsky, Eduardo
AU - Davila-Roman, Victor G.
AU - Delmez, James A.
PY - 2011/3
Y1 - 2011/3
N2 - Background and Objectives: Vascular calcification is a major contributor to morbidity and mortality in hemodialysis. The objective of this pilot study was to determine the feasibility, safety and efficacy of sodium thiosulfate (STS) in the progression of vascular calcification in hemodialysis patients. Methods: Chronic hemodialysis patients underwent a battery of cardiovascular tests. Those with coronary artery calcium (Agatston scores >50) received intravenous STS after each dialysis for 5 months (n = 22) and the tests were repeated. Changes in MDCT-determined calcification were assessed as the mean annualized rate of change in 3 vascular beds (coronary, thoracic and carotid arteries) and in L1-L2 vertebral bone density. Results: Although individual analyses showed coronary artery calcification progression in 14/22 subjects, there was no progression in the mean annualized rate of change of vascular calcification in the entire group. The L1-L2 vertebral bone density showed no changes. There were no correlations between rates of progression of vascular calcification and phosphorus, fetuin or C-reactive protein levels. Changes in coronary artery calcification scores correlated with those of the thoracic aorta. Conclusion: STS treatment is feasible, appears safe and may decrease the rate of progression of vascular calcification in hemodialysis patients. A large, randomized, controlled trial is warranted.
AB - Background and Objectives: Vascular calcification is a major contributor to morbidity and mortality in hemodialysis. The objective of this pilot study was to determine the feasibility, safety and efficacy of sodium thiosulfate (STS) in the progression of vascular calcification in hemodialysis patients. Methods: Chronic hemodialysis patients underwent a battery of cardiovascular tests. Those with coronary artery calcium (Agatston scores >50) received intravenous STS after each dialysis for 5 months (n = 22) and the tests were repeated. Changes in MDCT-determined calcification were assessed as the mean annualized rate of change in 3 vascular beds (coronary, thoracic and carotid arteries) and in L1-L2 vertebral bone density. Results: Although individual analyses showed coronary artery calcification progression in 14/22 subjects, there was no progression in the mean annualized rate of change of vascular calcification in the entire group. The L1-L2 vertebral bone density showed no changes. There were no correlations between rates of progression of vascular calcification and phosphorus, fetuin or C-reactive protein levels. Changes in coronary artery calcification scores correlated with those of the thoracic aorta. Conclusion: STS treatment is feasible, appears safe and may decrease the rate of progression of vascular calcification in hemodialysis patients. A large, randomized, controlled trial is warranted.
KW - Hemodialysis
KW - Sodium thiosulfate
KW - Vascular calcification
UR - http://www.scopus.com/inward/record.url?scp=78651407680&partnerID=8YFLogxK
U2 - 10.1159/000323550
DO - 10.1159/000323550
M3 - Article
C2 - 21242673
AN - SCOPUS:78651407680
SN - 0250-8095
VL - 33
SP - 131
EP - 138
JO - American Journal of Nephrology
JF - American Journal of Nephrology
IS - 2
ER -